Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cb9f654ff-qc88w Total loading time: 0 Render date: 2025-08-07T12:20:06.279Z Has data issue: false hasContentIssue false

Chapter 9 - The Management of HIV Infection, Opportunistic Infections and Complications of Other Causes of Immunocompromise

Published online by Cambridge University Press:  19 December 2019

Luke S. P. Moore  and
James C. Hatcher
Luke S. P. Moore
Affiliation:
Imperial College London
James C. Hatcher
Affiliation:
Great Ormond Street Hospital for Children
Get access

Summary

Patients living with human immunodeficiency virus (HIV) have particular health needs relating to their diagnosis, the opportunistic infections which can affect them, and the chronic disease management of their condition which is impacted by the disease process itself and the medication used to control it. Practitioners working with patients living with human immunodeficiency virus must hold knowledge of the pathophysiology and natural history of the disease, the therapeutic options available for virological control and the likely complication from HIV and the medications. Practitioners must be able to safely monitor and interpret the test results of patients living with human immunodeficiency virus. They must also be able to advise on strategies to decrease onwards transmission of HIV, including pre-and post-exposure prophylaxis. Practitioners managing patients living with human immunodeficiency virus must be able to identify and treat the opportunistic infections which may arise.

Information

Type
Chapter
Information
Infectious Diseases, Microbiology and Virology
A Q&A Approach for Specialist Medical Trainees
 , pp. 187 - 209
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Further Reading

INSIGHT START study Group, Lundgren, JD, Babiker, AG, Gordin, F, Emery, S, Grund, B, Sharma, S, Avihingsanon, A, Cooper, DA, Fätkenheuer, G, Llibre, JM, Molina, JM, Munderi, P, Schechter, M, Wood, R, Klingman, KL, Collins, S, Lane, HC, Phillips, AN, Neaton, JD. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.Google Scholar

Further Reading

Kalayjian, RC. The treatment of HIV-associated nephropathy. Adv Chronic Kidney Dis. 2010;17(1):59–71.Google Scholar

Further Reading

Burton, DR, Mascola, JR. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol. 2015;16:571–576.Google Scholar
The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.Google Scholar

Further Reading

Nelson, M, Dockrell, D, Edwards, S; BHIVA guidelines subcommittee. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med. 2011;12(S2):1–140.CrossRefGoogle Scholar

Further Reading

Nelson, M, Dockrell, D, Edwards, S; BHIVA Guidelines Subcommittee. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med. 2011;12(S2):1–140.CrossRefGoogle Scholar

Further Reading

Bower, M, Palfreeman, A, Alfa-Wali, M, Bunker, C, Burns, F, Churchill, D, Collins, S, Cwynarski, K, Edwards, S, Fields, P, Fife, K, Gallop-Evans, E, Kassam, S, Kulasegaram, R, Lacey, C, Marcus, R, Montoto, S, Nelson, M, Newsom-Davis, T, Orkin, C, Shaw, K, Tenant-Flowers, M, Webb, A, Westwell, S, Williams, M. British HIV association guidelines for HIV-associated malignancies 2014. HIV Med. 2014;15(S2):1–92.Google Scholar

Further Reading

Bower, M, Palfreeman, A, Alfa-Wali, M, Bunker, C, Burns, F, Churchill, D, Collins, S, Cwynarski, K, Edwards, S, Fields, P, Fife, K, Gallop-Evans, E, Kassam, S, Kulasegaram, R, Lacey, C, Marcus, R, Montoto, S, Nelson, M, Newsom-Davis, T, Orkin, C, Shaw, K, Tenant-Flowers, M, Webb, A, Westwell, S, Williams, M. British HIV association guidelines for HIV-associated malignancies 2014. HIV Med. 2014;15(S2):1–92.Google Scholar

Further Reading

Nelson, M, Dockrell, D, Edwards, S. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med. 2011;12(S2):1–140.Google Scholar

Further Reading

Churchill, D, Waters, L, Ahmed, N, Angus, B, Boffito, M, Bower, M, Dunn, D, Edwards, S, Emerson, C, Fidler, S, Fisher, M, Horne, R, Khoo, S, Leen, C, Mackie, N, Marshall, N, Monteiro, F, Nelson, M, Orkin, C, Palfreeman, A, Pett, S, Phillips, A, Post, F, Pozniak, A, Reeves, I, Sabin, C, Trevelion, R, Walsh, J, Wilkins, E, Williams, I, Winston, A. British HIV association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Med. 2016;17(S4):S2–S104.Google Scholar

Further Reading

Churchill, D, Waters, L, Ahmed, N, Angus, B, Boffito, M, Bower, M, Dunn, D, Edwards, S, Emerson, C, Fidler, S, Fisher, M, Horne, R, Khoo, S, Leen, C, Mackie, N, Marshall, N, Monteiro, F, Nelson, M, Orkin, C, Palfreeman, A, Pett, S, Phillips, A, Post, F, Pozniak, A, Reeves, I, Sabin, C, Trevelion, R, Walsh, J, Wilkins, E, Williams, I, Winston, A. British HIV association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Med. 2016;17(S4):S2–S104.Google Scholar

Further Reading

De Ruiter, A, Taylor, GP, Clayden, P, Dhar, J, Gandhi, K, Gilleece, Y, Harding, K, Hay, P, Kennedy, J, Low-Beer, N, Lyall, H, Palfreeman, A, O’Shea, S, Tookey, P, Tosswill, J, Welch, S, Wilkins, E. British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review). HIV Med. 2014;15(S4):1–77.Google Scholar
Ford, N, Mofenson, L, Shubber, Z, Calmy, A, Andrieux-Meyer, I, Vitoria, M, Shaffer, N, Renaud, F. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2014;28(S2):S123–S131.Google Scholar

Further Reading

Churchill, D, Waters, L, Ahmed, N, Angus, B, Boffito, M, Bower, M, Dunn, D, Edwards, S, Emerson, C, Fidler, S, Fisher, M, Horne, R, Khoo, S, Leen, C, Mackie, N, Marshall, N, Monteiro, F, Nelson, M, Orkin, C, Palfreeman, A, Pett, S, Phillips, A, Post, F, Pozniak, A, Reeves, I, Sabin, C, Trevelion, R, Walsh, J, Wilkins, E, Williams, I, Winston, A. British HIV association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Med. 2016;17(S4):S2–S104.Google Scholar
Waters, L, Jackson, A, Else, L, Rockwood, N, Newell, S, Back, D, Nelson, M, Gazzard, B, Boffito, M. Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily I patients on suppressive antiretroviral therapy. Antivir Ther. 2015;20:157–163.Google Scholar

Further Reading

Gilleece, Y, Chadwick, DR, Breuer, J, Hawkins, D, Smit, E, McCrae, LX, Pillay, D, Smith, N, Anderson, J. British HIV association guidelines for antiretroviral treatment of HIV-2 positive individuals 2010. HIV Med. 2010;11:611–619.Google Scholar

Further Reading

Cresswell, F, Waters, L, Briggs, E, Fox, J, Harbottle, J, Hawkins, D, Murchie, M, Radcliffe, K, Rafferty, P, Rodger, A, Fisher, M. UK guideline for the use of HIV post-exposure prophylaxis following sexual exposure, 2015. Int J STD AIDS. 2016;27(9):713–738.Google Scholar

Further Reading

Lopez Bernaldo de Quiros, JC, Miro, JM, Peña, JM, Podzamczer, D, Alberdi, JC, Martínez, E, Cosin, J, Claramonte, X, Gonzalez, J, Domingo, P, Casado, JL, Ribera, E. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med. 2001;344(3):159.Google Scholar

Further Reading

Nelson, M, Dockrell, D, Edwards, S. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med. 2011;12(S2):1–140.Google Scholar

Further Reading

Lenaerts, L, De Clercq, E, Naesens, L. Clinical features and treatment of adenovirus infections. Rev Med Virol. 2008;18(6):357–374.Google Scholar

Further Reading

Caserta, MT, Hall, CB, Schnabel, K, Lofthus, G, Marino, A, Shelley, L, Yoo, C, Carnahan, J, Anderson, L, Wang, H. Diagnostic assays for active infection with human herpesvirus 6 (HHV-6). J Clin Virol. 2010;48(1):55–57.Google Scholar

Further Reading

Pastor, FJ, Guarro, J. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin Microbiol Infect. 2006 Oct;12(10):948–960.Google Scholar

Further Reading

Nucci, M, Marr, KA, Bvehreschild, MJ, de Souza, CA, Velasco, E, Cappellano, P, Carlesse, F, Queiroz-Telles, F, Sheppard, DC, Kindo, A, Cesaro, S, Hamerschlak, N, Solza, C, Heinz, WJ, Schaller, M, Atalla, A, Arikan-Akdagli, S, Bertz, H, Galvão Castro, C Jr, Herbrecht, R, Hoenigl, M, Härter, G, Hermansen, NE, Josting, A, Pagano, L, Salles, MJ, Mossad, SB, Ogunc, D, Pasqualotto, AC, Araujo, V, Troke, PF, Lortholary, O, Cornely, OA, Anaissie, E. Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect. 2014;20(6):580–585.Google Scholar

Further Reading

Aguilar-Guisado, M, Espigado, I, Martin-Pena, A, Gudiol, C, Royo-Cebrecos, C, Falantes, J, Vázquez-López, L, Montero, MI, Rosso-Fernández, C, de la Luz Martino, M, Parody, R, González-Campos, J, Garzón-López, S, Calderón-Cabrera, C, Barba, P, Rodríguez, N, Rovira, M, Montero-Mateos, E, Carratalá, J, Pérez-Simón, JA, Cisneros, JM. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematol. 2017;4(12):e573–e583.Google Scholar
Averbuch, D, Orasch, C, Cordonnier, C, Livermore, DM, Mikulska, M, Viscoli, C, Gyssens, IC, Kern, WV, Klyasova, G, Marchetti, O, Engelhard, D, Akova, M. European guidelines for empirical antibacterial therapy for neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukaemia. Haematologica. 2013;98(12):1826–1835.Google Scholar
National Institute for Health and Care Excellence. Neutropenic sepsis: prevention and management in people with cancer. NICE guideline (CG151). 2012. Available at: www.nice.org.uk/guidance/cg151Google Scholar

Further Reading

Patterson, TF, Thompson, GR 3rd, Denning, DW, Fishman, JA, Hadley, S, Herbrecht, R, Kontoyiannis, DP, Marr, KA, Morrison, VA, Nguyen, MH, Segal, BH, Steinbach, WJ, Stevens, DA, Walsh, TJ, Wingard, JR, Young, JA, Bennett, JE. Practice guidelines for the diagnosis and management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60.Google Scholar

Further Reading

Stringer, J, Beard, C, Miller, R, Wakefield, A. A new name (Pneumocystis jirovecii) for pneumocystis from humans. Emerg Infect Dis. 2002;8(9):891–896.CrossRefGoogle Scholar

Further Reading

Mauch, L, Lun, A, O’Gorman, MR, Harris, JS, Schulze, I, Zychlinsky, A, Fuchs, T, Oelschlägel, U, Brenner, S, Kutter, D, Rösen-Wolff, A, Roesler, J. Chronic granulomatous disease (CGD) and complete myeloperoxidase deficiency both yield strongly reduced dihydrorhodamine 123 test signals but can be easily discerned in routine testing for CGD. Clin Chem. 2007;53(5):890.CrossRefGoogle ScholarPubMed

Further Reading

Health Protection Agency. Guidelines for Assessing the Microbiological Safety of Ready-to-Eat Foods. London: Health Protection Agency. 2009. Available at: www.gov.uk/government/publications/ready-to-eat-foods-microbiological-safety-assessment-guidelinesGoogle Scholar

Further Reading

Anders, BJ, Lauer, BA, Paisley, JW, Reller, LB. Double-blind placebo controlled trial of erythromycin for treatment of Campylobacter enteritis. Lancet. 1982;1(8264):131–132.Google Scholar
Janssen, R, Krogfelt, KA, Cawthraw, S, van Pelt, W, Wagenaar, JA, Owen, RJ. Host-pathogen interactions in Campylobacter infections: the host perspective. Clin Microbiol Rev. 2008;21(3):505–518.CrossRefGoogle ScholarPubMed

Further Reading

Heinz, WJ, Buchheidt, D, Chistopeit, M, von Lilienfeld-Toal, M, Cornely, OA, Einsele, H, Karthaus, M, Link, H, Mahlberg, R, Neumann, S, Ostermann, H, Penack, O, Ruhnke, M, Sandherr, M, Schiel, X, Vehreschild, JJ, Weissinger, F, Maschmeyer, G. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO). Ann Hematol. 2017;96(11):1775–1792.Google Scholar
National Institute for Health and Care Excellence. Neutropenic sepsis: prevention and management in people with cancer. NICE guideline (CG151). 2012. Available at: www.nice.org.uk/guidance/cg151Google Scholar

Accessibility standard: Unknown

Accessibility compliance for the PDF of this book is currently unknown and may be updated in the future.

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×